HomeLSTA • NASDAQ
Lisata Therapeutics Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 4.41M | -17.28% |
Net income | -4.25M | 13.81% |
Net profit margin | — | — |
Earnings per share | -0.49 | 16.95% |
EBITDA | -4.37M | 17.45% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 19.00M | -47.02% |
Total assets | 21.76M | -43.04% |
Total liabilities | 4.64M | -2.58% |
Total equity | 17.12M | — |
Shares outstanding | 8.82M | — |
Price to book | 1.04 | — |
Return on assets | -47.04% | — |
Return on capital | -58.17% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -4.25M | 13.81% |
Cash from operations | -3.34M | -32.72% |
Cash from investing | 5.15M | 181.68% |
Cash from financing | 353.00K | — |
Net change in cash | 2.16M | 124.62% |
Free cash flow | -1.84M | -115.02% |
Previous close
$2.05
Day range
$2.01 - $2.11
Year range
$1.87 - $4.20
Market cap
17.82M USD
Avg Volume
116.37K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
26
